波色单双

Josephine Elia, MD

Psychiatry

Primary Office

波色单双 Hospital, Delaware 波色单双 Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803 Appointment: (800) 416-4441

Other Offices

Education & Training

Fellowship

  • Psychiatry - National Institute of Health Clinical Center Prog, 1991
  • Child & Adolescent Psychiatry - Drexel University College of Medicine/Hahnemann, 1987

Internship Residency

  • Psychiatry - Medical College of Pennsylvania, 1984

Medical/Dental School

  • MD - Drexel University, 1982

Board Certifications

  • American Board of Psychiatry & Neurology/Psychiatry
  • American Board of Psychiatry & Neurology/Child & Adolescent Psychiatry

Awards & Recognition

  • 2016 Philadelphia Magazine's Top Doctors
  • 2015 Philadelphia Magazine's Top Doctors
  • 2014 Best Doctors in America
  • 2014 Delaware Today magazine, Top Doctors
  • 2014 Philadelphia Magazine's Top Doctors

Insurance Accepted

  • Aetna Better Health FL Medicaid and Healthy Kids
  • Aetna Better Health PA Kids HMO
  • Aetna HMO
  • Aetna HMO/POS/PPO/EPO
  • Aetna PPO/POS/EPO
  • Amerihealth Caritas Delaware
  • Blue Cross and Blue Shield HMO
  • Blue Cross and Blue Shield Non HMO
  • Blue Cross Blue Shield Florida Blue Select
  • Cigna & Great West HMO/POS Open Access
  • Cigna & Great West PPO/EPO
  • Cigna Behavioral Health
  • Cigna/Great West HMO EPO POS
  • Cigna/Great West PPO
  • Community Care Behavioral Health
  • Compsych DE
  • Delaware First Health
  • Devon Health Services
  • Employers Health Network PPO
  • Fidelis Care NJ Medicaid HMO
  • First Health Aetna PPO/EPO
  • First Health/Affordable PPO
  • Florida Medicaid
  • Florida Medicare
  • Geisinger Health Plan Commercial
  • Global Medical Managment DE/PA
  • Health First Health Plans
  • HealthSmart Health Plans PPO
  • Highmark Blue Cross Blue Shield of Delaware
  • Highmark Medicaid Health Options
  • Horizon Blue Cross Blue Shield of New Jersey
  • HUMANA HEALTHY HORIZONS (FKA HUMANA MEDICAID)
  • Humana HMO/POS
  • Humana PPO/EPO
  • Independance Blue Cross/Amerihealth/Keystone Health Plan
  • Insurance Administrators of America
  • INTEGRA Administrative Group (ClaimsBridge)
  • Lifetrac Transplant
  • Maryland Medicaid
  • MHNET Behavioral Health
  • Molina Healthcare Medicaid
  • Multiplan PPO
  • National Transplant (Humana)
  • New Jersey Medicaid
  • Olympus Managed Healthcare PPO ORL
  • Plan Vista/NPPN PPO
  • Preferred Healthcare PPO
  • Private Health Care Systems (PHCS)
  • Qualcare HMO/POS/PPO
  • Star Healthcare Network
  • Sunshine State Health Plan Medicaid
  • Three Rivers Provider Network
  • Tricare/Humana Military Health Services/CHAMPVA
  • United Healthcare Commercial Products
  • United Healthcare Community Plan Medicaid
  • Volusia Health Network PPO/EPO

  • Schizophrenia and Psychotic Disorders

  • Statistical and functional convergence of common and rare genetic influences on autism at chromosome 16p; Nature Genetics; (2022).

  • Statistical and functional convergence of common and rare variant risk for autism spectrum disorders at chromosome 16p; medRxiv; (2022).

  • Author Correction: Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder (Nature Communications, (2021), 12, 1, (576), 10.1038/s41467-020-20443-2); Nature Communications; (2021).

  • Epigenetics in child psychiatry; Epigenetics in Psychiatry; (2021).

  • Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder; Nature Communications; (2021).

  • Application of Telemedicine Technology to Facilitate Diagnosis of Pediatric Postintensive Care Syndrome; Telemedicine and e-Health; (2020).

  • Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations; Nature Communications; (2020).

  • Shared genetic background between children and adults with attention deficit/hyperactivity disorder; bioRxiv; (2019).

  • Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders; Cell; (2019).

  • Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder; Nature Genetics; (2019).

  • A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder; Biological Psychiatry; (2018).

  • Attention Deficit Hyperactivity Disorder and Anxiety; Complex Disorders in Pediatric Psychiatry: A Clinician's Guide; (2018).

  • Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling; Nature Communications; (2018).

  • Pediatric Catatonia; Complex Disorders in Pediatric Psychiatry: A Clinician's Guide; (2018).

  • Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part i - Psychiatric and Behavioral Interventions; Journal of Child and Adolescent Psychopharmacology; (2017).

  • Genetic Overlap Between Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder: Evidence From Genome-wide Association Study Meta-analysis; Biological Psychiatry; (2017).

  • Psychiatric gene discoveries shape evidence on ADHD's biology; Molecular Psychiatry; (2016).

  • Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways; Nature Neuroscience; (2015).

  • Attention-deficit hyperactivity disorder and pharmacotherapy鈥攑ast, present, and future: A review of the changing landscape of drug therapy; Therapeutic Innovation and Regulatory Science; (2015).

  • Converging evidence does not support GIT1 as an ADHD risk gene; American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics; (2015).

  • Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder; American Journal of Human Genetics; (2015).

  • A link between perianal strep and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS); Journal of Neuropsychiatry and Clinical Neurosciences; (2014).

  • Epigenetics in Child Psychiatry; Epigenetics in Psychiatry; (2014).

  • Polygenic transmission and complex neuro developmental network for attention deficit hyperactivity disorder: Genome-wide association study of both common and rare variants; American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics; (2013).

  • Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs; Nature Genetics; (2013).

  • Attention deficit hyperactivity disorder characteristics: II. Clinical correlates of irritable mood; Journal of Affective Disorders; (2013).

  • ADHD etiology; ADHD: Clinical Management of Attention Deficit Hyperactivity Disorder; (2013).

  • Pharmacological treatment and prognosis of ADHD; ADHD: Clinical Management of Attention Deficit Hyperactivity Disorder; (2013).

  • Associations between psychiatric comorbidities and sleep disturbances in children with attention-deficit/hyperactivity disorder; Journal of Developmental and Behavioral Pediatrics; (2012).

  • Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: The role of rare variants and duplications at 15q13.3; American Journal of Psychiatry; (2012).

  • Epigenetics: Genetics versus life experiences; Current Topics in Behavioral Neurosciences; (2012).

  • Attention-deficit/hyperactivity disorder genomics: Update for clinicians; Current Psychiatry Reports; (2012).

  • A family-school intervention for children with ADHD: Results of a randomized clinical trial; Journal of Consulting and Clinical Psychology; (2012).

  • A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD; Molecular Psychiatry; (2012).

  • Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD; American Journal of Psychiatry; (2012).

  • Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder; Nature Genetics; (2012).

  • Pediatric cardiovascular safety: Challenges in drug and device development and clinical application; American Heart Journal; (2012).

  • Rare structural variation of synapse and neurotransmission genes in autism; Molecular Psychiatry; (2012).

  • Stimulant treatment in healthy young people with ADHD is not associated with increased risk of cardiovascular events; Evidence-Based Mental Health; (2012).

  • What can ADHD without comorbidity teach us about comorbidity?; Research in Developmental Disabilities; (2012).

  • Genome-wide association study in German patients with attention deficit/hyperactivity disorder; American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics; (2011).

  • Methylphenidate transdermal system: Clinical applications for attention-deficit/hyperactivity disorder; Expert Review of Clinical Pharmacology; (2011).

  • Structural variations in attention-deficit hyperactivity disorder; The Lancet; (2011).

  • Exome sequencing and unrelated findings in the context of complex disease research: ethical and clinical implications.; Discovery medicine; (2011).

  • Analysis of GWAS top hits in ADHD suggests association to two polymorphisms located in genes expressed in the cerebellum; American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics; (2010).

  • Erratum: Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes (Molecular Psychiatry (2010) 15 (637-646) DOI: 10.1038/mp.2009.57); Molecular Psychiatry; (2010).

  • A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication; Molecular Psychiatry; (2010).

  • Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: What is known and how should it influence prescribing in children?; Pediatric Drugs; (2010).

  • Meta-analysis of genome-wide association studies of attention-deficit/ hyperactivity disorder; Journal of the American Academy of Child and Adolescent Psychiatry; (2010).

  • Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes; Molecular Psychiatry; (2010).

  • Parental ADHD Status and its Association with Proband ADHD Subtype and Severity; Journal of Pediatrics; (2010).

  • Nocturnal Enuresis: A Suggestive Endophenotype Marker for a Subgroup of Inattentive Attention-Deficit/Hyperactivity Disorder; Journal of Pediatrics; (2009).

  • ADHD latent class clusters: DSM-IV subtypes and comorbidity; Psychiatry Research; (2009).

  • Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: Suggestive association signals in ADRA1A; Psychiatric Genetics; (2009).

  • Genomewide Association Studies: History, Rationale, and Prospects for Psychiatric Disorders; American Journal of Psychiatry; (2009).

  • High-resolution mapping and analysis of copy number variations in the human genome: A data resource for clinical and research applications; Genome Research; (2009).

  • ADHD characteristics: I. Concurrent co-morbidity patterns in children & adolescents; Child and Adolescent Psychiatry and Mental Health; (2008).

  • Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: A scientific statement from the American Heart Association Council on cardiovascular disease in the Young Congenital Cardiac Defects Committee and the Council On Cardiovascular Nursing; Circulation; (2008).

  • ADHD genetics: 2007 update; Current Psychiatry Reports; (2007).

  • Depressive symptoms and SSRI use in pediatric oncology patients; Pediatric Blood and Cancer; (2007).

  • Lisdexamfetamine dimesylate; Nature Reviews Drug Discovery; (2007).

  • Neurodevelopmental and neuropsychiatric disorders; Pediatric PET Imaging; (2006).

  • PANDAS with catatonia: A case report. Therapeutic response to lorazepam and plasmapheresis; Journal of the American Academy of Child and Adolescent Psychiatry; (2005).

  • Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): A case report and review of the literature; Clinical Rheumatology; (2005).

  • A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder; Journal of the American Academy of Child and Adolescent Psychiatry; (2004).

  • 49th Annual meeting of the American academy of child and adolescent psychiatry; Expert Opinion on Pharmacotherapy; (2003).

  • Atomoxetine: Viewpoints; Pediatric Drugs; (2003).

  • Treatment of attention-deficit - Hyperactivity disorder; New England Journal of Medicine; (1999).

  • Multicenter open-label sertraline study in adolescent outpatients with major depression; Journal of the American Academy of Child and Adolescent Psychiatry; (1999).

  • Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders; Journal of Clinical Psychiatry; (1999).

  • Pancreatitis associated with serotonin-dopamine antagonists [1]; Journal of Child and Adolescent Psychopharmacology; (1997).

  • Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: Effects of stimulant and dose; Journal of the American Academy of Child and Adolescent Psychiatry; (1997).

  • Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder; Neuropsychopharmacology; (1996).

  • Letter to the editor; Journal of the American Academy of Child and Adolescent Psychiatry; (1995).

  • THE SAFETY OF DESIPRAMINE; Journal of the American Academy of Child and Adolescent Psychiatry; (1994).

  • Measurement of aggression in children with disruptive behavior disorders; Journal of Offender Rehabilitation; (1994).

  • Letter to the editor; Journal of the American Academy of Child and Adolescent Psychiatry; (1994).

  • Letter to the editor; Journal of the American Academy of Child and Adolescent Psychiatry; (1994).

  • Effect of dextroamphetamine and methylphenidate on calcium and magnesium concentration in hyperactive boys; Psychiatry Research; (1994).

  • Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder; Psychiatry Research; (1994).

  • ANTIDEPRESSANT MECHANISMS; Journal of the American Academy of Child and Adolescent Psychiatry; (1994).

  • ADHD AND THE THYROID; Journal of the American Academy of Child and Adolescent Psychiatry; (1994).

  • Thyroid Function and Attention-Deficit Hyperactivity Disorder; Journal of the American Academy of Child and Adolescent Psychiatry; (1994).

  • Antidepressant Treatments in Children and Adolescents I. Affective Disorders; Journal of the American Academy of Child and Adolescent Psychiatry; (1993).

  • Antidepressant Treatments in Children and Adolescents: II. Anxiety, Physical, and Behavioral Disorders; Journal of the American Academy of Child and Adolescent Psychiatry; (1993).

  • Classroom Academic Performance: Improvement with both Methylphenidate and Dextroamphetamine in ADHD Boys; Journal of Child Psychology and Psychiatry; (1993).

  • Drug Treatment for Hyperactive Children: Therapeutic Guidelines; Drugs; (1993).

  • Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease; Brain; (1992).

  • Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders?; Psychiatry Research; (1991).

  • P.R.N. medications in child psychiatric patients: A pilot placebo-controlled study; Journal of Clinical Psychiatry; (1991).

  • Stimulants and antidepressant pharmacokinetics in hyperactive children; Psychopharmacology Bulletin; (1991).

  • Attention-deficit hyperactivity disorder; Clinical Pharmacy; (1990).

  • Motor/vocal tics and compulsive behaviors on stimulant drugs: Is there a common vulnerability?; Psychiatry Research; (1990).

  • Stimulant drug treatment of hyperactivity: Biochemical correlates; Clinical Pharmacology and Therapeutics; (1990).

  • Teratogenicity of psychotherapeutic medications; Psychopharmacology Bulletin; (1987).

  • English
  • Italian